Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Mar 15, 2019

ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results

Feb 21, 2019

ProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors

Jan 31, 2019

Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease

Jan 17, 2019

ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences

Dec 18, 2018

ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China Focus@JPMWeek

Dec 17, 2018

ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board

Nov 20, 2018

ProMIS Neurosciences Issues Year-to Date Update, Highlighting 2018 Accomplishments

Nov 13, 2018

ProMIS Neurosciences Announces Third Quarter 2018 Results

Nov 6, 2018

ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease

Oct 31, 2018

ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer's Disease and Other Dementias

  • arrow_back
  • 1…
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2026 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy